Journal of the American Society of Hypertension
Volume 2, Issue 4 , Pages 227-238 , July 2008

Peroxisome proliferator-activated receptors and the vascular system: beyond their metabolic effects

  • Chiara Marchesi, MD
    • ,
  • Ernesto L. Schiffrin, MD, PhD, FRSC, FRCPC

      Affiliations

    • Corresponding Author InformationCorresponding author: Ernesto L. Schiffrin, MD, PhD, FRSC, FRCPC, Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, #B-127, 3755 Côte Ste-Catherine Road, Montreal, Quebec, Canada H3T 1E2. Tel: 514-340-7538; fax: 514-340-7539.

Received 21 November 2007 ,Accepted 28 December 2007.

References 

  1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645–650
  2. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20:649–688
  3. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168–1178
  4. Ziouzenkova O, Plutzky J. Lipolytic PPAR activation: new insights into the intersection of triglycerides and inflammation?. Curr Opin Clin Nutr Metab Care. 2004;7:369–375
  5. Han SH, Quon MJ, Koh KK. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-α activators. Hypertension. 2005;46:1086–1092
  6. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ, a lipid-activated transcription factor. Cell. 1994;79:1147–1156
  7. Olefsky JM, Saltiel AR. PPAR γ and the treatment of insulin resistance. Trends Endocrinol Metab. 2000;11:362–368
  8. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661–1669
  9. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1994;91:7355–7359
  10. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology. 1996;137:354–366
  11. Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006;26:28–40
  12. Muscat GE, Dressel U. Cardiovascular disease and PPARδ: targeting the risk factors. Curr Opin Investig Drugs. 2005;6:887–894
  13. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol. 2000;129:823–834
  14. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension. 2003;42:664–668
  15. Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol. 2005;288:H1037–H1043
  16. Hsueh WA, Law RE. PPARγ and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol. 2001;21:1891–1895
  17. Planavila A, Rodriguez-Calvo R, Jove M, Michalik L, Wahli W, Laguna JC, et al. Peroxisome proliferator-activated receptor β/δ activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res. 2005;65:832–841
  18. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, et al. PPARα activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension. 2002;40:866–871
  19. Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-γ agonist in hypercholesterolemia. Circulation. 2003;108:2805–2811
  20. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol. 2001;169:453–459
  21. Takata Y, Kitami Y, Yang ZH, Nakamura M, Okura T, Hiwada K. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-δ and peroxisome proliferator-activated receptor-γ. Circ Res. 2002;91:427–433
  22. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, et al. Transcriptional repression of atherogenic inflammation: modulation by PPARδ. Science. 2003;302:453–457
  23. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPARγ. Nature. 2005;437:759–763
  24. Blanquart C, Mansouri R, Paumelle R, Fruchart JC, Staels B, Glineur C. The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor α. Mol Endocrinol. 2004;18:1906–1918
  25. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus, and hypertension. Nature. 1999;402:880–883
  26. Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator-activated receptor α (PPAR α) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun. 1998;246:370–374
  27. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature. 1998;393:790–793
  28. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273:25573–25580
  29. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, et al. Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000;164:6503–6508
  30. Lee H, Shi W, Tontonoz P, Wang S, Subbanagounder G, Hedrick CC, et al. Role for peroxisome proliferator-activated receptor–α in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circulation Research. 2000;87:516–521
  31. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999;99:3125–3131
  32. Inoue I, Goto S, Matsunaga T, Nakajima T, Awata T, Hokari S, et al. The ligands/activators for peroxisome proliferator-activated receptor α (PPARα) and PPARγ increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001;50:3–11
  33. Goya K, Sumitani S, Xu X, Kitamura T, Yamamoto H, Kurebayashi S, et al. Peroxisome proliferator-activated receptor α agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24:658–663
  34. Irukayama-Tomobe Y, Miyauchi T, Kasuya Y, Sakai S, Goto K, Yamaguchi I. Activation of peroxisome proliferator-activated receptor-α decreases endothelin-1-induced p38 mitogen-activated protein kinase activation in cardiomyocytes. J Cardiovasc Pharmacol. 2004;44:S358–S361
  35. Israelian-Konaraki Z, Reaven PD. Peroxisome proliferator-activated receptor-α and atherosclerosis: from basic mechanisms to clinical implications. Cardiol Rev. 2005;13:240–246
  36. Diep QN, Touyz RM, Schiffrin EL. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-α ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension. 2000;36:851–855
  37. Hennuyer N, Poulain P, Madsen L, Berge RK, Houdebine LM, Branellec D, et al. Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response. Circulation. 1999;99:2445–2451
  38. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther. 1998;36:345–349
  39. Delerive P, De BK, Besnard S, Vanden BW, Peters JM, Gonzalez FJ, et al. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem. 1999;274:32048–32054
  40. Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-α via inhibition of the protein kinase C signaling pathway. Circ Res. 2006;98:361–369
  41. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol. 2003;23:45–51
  42. Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol. 1997;80:1125–1129
  43. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–1245
  44. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol (Lopid Coronary Angiography Trial (LOCAT) Study Group). Circulation. 1997;96:2137–2143
  45. Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care. 2003;26:1513–1517
  46. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD Study): randomized controlled trial. Lancet. 2005;366:1849–1861
  47. Flavell DM, Jamshidi Y, Hawe E, Pineda TI, Taskinen MR, Frick MH, et al. Peroxisome proliferator-activated receptor α gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation. 2002;105:1440–1445
  48. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation. 2000;101:1773–1779
  49. Playford DA, Watts GF, Best JD, Burke V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol. 2002;90:1254–1257
  50. Satoh H, Tsukamoto K, Hashimoto Y, Hashimoto N, Togo M, Hara M, et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARγ on vascular endothelial function. Biochem Biophys Res Commun. 1999;254:757–763
  51. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation. 2000;101:1311–1318
  52. Diep QN, Schiffrin EL. Increased expression of peroxisome proliferator-activated receptor-α and -γ in blood vessels of spontaneously hypertensive rats. Hypertension. 2001;38:249–254
  53. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79–82
  54. Artwohl M, Holzenbein T, Furnsinn C, Freudenthaler A, Huttary N, Waldhausl WK, et al. Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells. Thromb Haemost. 2005;93:810–815
  55. Zhang J, Fu M, Zhao L, Chen YE. 15-Deoxy-prostaglandin J(2) inhibits PDGF-A and -B chain expression in human vascular endothelial cells independent of PPARγ. Biochem Biophys Res Commun. 2002;298:128–132
  56. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-12, 14-prostaglandin J2. J Biol Chem. 1999;274:17042–17048
  57. Hannan KM, Dilley RJ, de Dios ST, Little PJ. Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta. Arterioscler Thromb Vasc Biol. 2003;23:762–768
  58. Bruemmer D, Blaschke F, Law RE. New targets for PPARγ in the vessel wall: implications for restenosis. Int J Obes (Lond). 2005;29:S26–S30
  59. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor-γ ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:52–57
  60. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM. Peroxisome proliferator-activated receptor-γ ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor γ-dependent mechanisms. Arterioscler Thromb Vasc Biol. 2005;25:1810–1816
  61. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82–86
  62. Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol. 2000;20:4699–4707
  63. Ricote M, Huang JT, Welch JS, Glass CK. The peroxisome proliferator-activated receptor (PPARγ) as a regulator of monocyte/macrophage function. J Leukoc Biol. 1999;66:733–739
  64. von Knethen A, Brune B. Activation of peroxisome proliferator-activated receptor-γ by nitric oxide in monocytes/macrophages down-regulates p47phox and attenuates the respiratory burst. J Immunol. 2002;169:2619–2626
  65. Diep QN, El MM, Cohn JS, Endemann D, Amiri F, Virdis A, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation. 2002;105:2296–2302
  66. Abe M, Hasegawa K, Wada H, Morimoto T, Yanazume T, Kawamura T, et al. GATA-6 is involved in PPARγ-mediated activation of differentiated phenotype in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23:404–410
  67. Wakino S, Kintscher U, Liu Z, Kim S, Yin F, Ohba M, et al. Peroxisome proliferator-activated receptor-γ ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cδ pathway in vascular smooth muscle cells. J Biol Chem. 2001;276:47650–47657
  68. Bruemmer D, Yin F, Liu J, Berger JP, Sakai T, Blaschke F, et al. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor-γ in vascular smooth muscle cells. Circ Res. 2003;93:e38–e47
  69. Bruemmer D, Yin F, Liu J, Berger JP, Kiyono T, Chen J, et al. Peroxisome proliferator-activated receptor-γ inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells. Mol Endocrinol. 2003;17:1005–1018
  70. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, et al. Expression of the peroxisome proliferator-activated receptor-γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low-density lipoprotein. Proc Natl Acad Sci U S A. 1998;95:7614–7619
  71. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996;98:1897–1905
  72. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor-γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106:523–531
  73. de Dios ST, Bruemmer D, Dilley RJ, Ivey ME, Jennings GL, Law RE, et al. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-γ ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation. 2003;107:2548–2550
  74. Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, et al. Anti-inflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension. 2002;40:687–693
  75. Ditiatkovski M, Toh BH, Bobik A. GM-CSF deficiency reduces macrophage PPAR-γ expression and aggravates atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:2337–2344
  76. Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, et al. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem. 2005;280:22212–22221
  77. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res. 2007;100:1442–1451
  78. Paumelle R, Staels B. Peroxisome proliferator-activated receptors mediate pleiotropic actions of statins. Circ Res. 2007;100:1394–1395
  79. Barlic J, Zhang Y, Foley JF, Murphy PM. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor γ-dependent pathway. Circulation. 2006;114:807–819
  80. Thorp E, Kuriakose G, Shah YM, Gonzalez FJ, Tabas I. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor null mice. Circulation. 2007;116:2182–2190
  81. Gao DF, Niu XL, Hao GH, Peng N, Wei J, Ning N, et al. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells—role of PPAR-γ in vascular fibrosis. Biochem Pharmacol. 2007;73:185–197
  82. Nakamura T, Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong Y, et al. Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke. 2007;38:3016–3022
  83. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, et al. Identification of CD36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet. 1999;21:76–83
  84. Ceolotto G, Gallo A, Papparella I, Franco L, Murphy E, Iori E, et al. Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler Thromb Vasc Biol. 2007;27:2627–2633
  85. Wang CH, Ciliberti N, Li SH, Szmitko PE, Weisel RD, Fedak PW, et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation. 2004;109:1392–1400
  86. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004;109:2058–2067
  87. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet. 2005;366:1279–1289
  88. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679–684
  89. Sarafidis PA, Lasaridis AN, Nilsson PM, Mouslech TF, Hitoglou-Makedou AD, Stafylas PC, et al. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension (An open-label observational study). Metabolism. 2005;54:1236–1242
  90. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation. 2003;107:2664–2669
  91. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation. 2003;107:1954–1957
  92. Hodis HN, Mack WJ, Zheng L, Li Y, Torres M, Sevilla D, et al. Effect of peroxisome proliferator-activated receptor-γ agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes. Diabetes Care. 2006;29:1545–1553
  93. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes (A randomized trial). JAMA. 2006;296:2572–2581
  94. Rosmarakis ES, Falagas ME. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J. 2007;154:144–150
  95. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26:2493–2499
  96. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol. 2003;42:1757–1763
  97. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol. 2004;24:930–934
  98. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2004;93:362–365
  99. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471
  100. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone (A meta-analysis). JAMA. 2007;298:1189–1195
  101. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med. 2007;357:28–38
  102. Nathan DM. Rosiglitazone and cardiotoxicity—weighing the evidence. N Engl J Med. 2007;357:64–66
  103. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus (A meta-analysis of randomized trials). JAMA. 2007;298:1180–1188
  104. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A Comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547–1554
  105. Berhanu P, Kipnes MS, Khan MA, Perez AT, Kupfer SF, Spanheimer RG, et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diabetes Vasc Dis Res. 2006;3:39–44
  106. Francis GA, Annicotte JS, Auwerx J. PPAR-α effects on the heart and other vascular tissues. Am J Physiol Heart Circ Physiol. 2003;285:H1–H9
  107. Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor-γ: implications for cardiovascular disease. Hypertension. 2004;43:297–305
  108. De Ciuceis, Amiri F, Iglarz M, Cohn JS, Touyz RM, Schiffrin EL. Synergistic vascular protective effects of combined low doses of PPARα and PPARγ activators in angiotensin II-induced hypertension in rats. Br J Pharmacol. 2007;151:45–53
  109. Harrity T, Farrelly D, Tieman A, Chu C, Kunselman L, Gu L, et al. Muraglitazar, a novel dual (α/γ) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Diabetes. 2006;55:240–248
  110. Muraglitazar BD. (Bristol–Myers Squibb/Merck). Curr Opin in Investig Drugs. 2005;6:427–434
  111. Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, et al. Muraglitazar, a dual (α/γ) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005;27:1181–1195
  112. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294:2581–2586
  113. Fagerberg B, Edwards S, Halmos T, Lopatynski J, Schuster H, Stender S, et al. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia. 2005;48:1716–1725
  114. Verreth W, Ganame J, Mertens A, Bernar H, Herregods MC, Holvoet P. Peroxisome proliferator-activated receptor-α,γ-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice. Arterioscler Thromb Vascular Biol. 2006;26:922–998
  115. Zadelaar AS, Boesten LS, Jukema JW, van Vlijmen BJ, Kooistra T, Emeis JJ, et al. Dual PPARα/γ agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice. Arterioscler Thromb Vascular Biol. 2006;26:2560–2566
  116. Chira EC, McMillen TS, Wang S, Haw A, O'Brien KD, Wight TN, et al. Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, reduces atherosclerosis in female low-density lipoprotein receptor deficient mice. Atherosclerosis. 2007;195:100–109

 This work was supported by Canadian Institutes of Health Research Grants 37917 and 82790 and a Canada Research Chair on Hypertension and Vascular Research to Dr. Schiffrin.

PII: S1933-1711(08)00002-8

doi: 10.1016/j.jash.2007.12.007

Journal of the American Society of Hypertension
Volume 2, Issue 4 , Pages 227-238 , July 2008

Article Tools

* Image Usage & Resolution